ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Aravive Biologics Achieves Proof-of-Mechanism for Novel GAS6-AXL Pathway Inhibitor, AVB-S6-500, in Ongoing Phase 1 Trial
May 14, 2018Aravive Biologics, Inc. announced today that the company has demonstrated clinical proof-of-mechanism for AVB-S6-500 in neutralizing GAS6, based on analysis of the single ascending dose portion of the ongoing Phase 1 study (32 subjects). -
WuXi Biologics and Aravive Biologics to Form Strategic Manufacturing Collaboration Following Success
January 31, 2018WuXi Biologics today announced plans to expand their biologics manufacturing collaboration, based on the rapid success achieved in the process development, scale-up and cGMP manufacture of Aravive's lead drug candidate, AVB-S6-50
Pharma Sources Insight January 2025
